Healtheconbot, 08 Mar 2017 #HealthEconJA Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative…
Healtheconbot, 08 Mar 2017 #HealthEconJA Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative…